Meta-analysis of the efficacy between gemcitabine-alone and gemcitabine-based chemotherapy applied in advanced pancreatic cancer.
- Author:
Kun SONG
1
;
Bin LI
;
Wei-jia SUN
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Clinical Trials, Phase III as Topic; Deoxycytidine; administration & dosage; analogs & derivatives; therapeutic use; Humans; Pancreatic Neoplasms; drug therapy; Randomized Controlled Trials as Topic; Treatment Outcome
- From: Chinese Journal of Surgery 2011;49(9):839-842
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy of gemcitabine (GEM) alone and gemcitabine based combination chemotherapy (GEMCOM) on advanced pancreatic cancer.
METHODSKeywords Phase III, gemcitabine and pancreatic cancer were used to search and collect Phase III-randomized references about gemcitabine and gemcitabine-based combination chemotherapy applied on advanced pancreatic cancer. A references-based meta-analysis was made to compare the efficacy between GEM and GEMCOM. Before that, test for heterogeneity was committed. Fixed effect model was used if the I(2) ≤ 50%, and random effect model was used if not. The evaluating indicators were overall response rate and 1-year survival rate.
RESULTSThere were 14 randomized controlled trial (RCT) and 10 RCT enrolled in overall response rate analysis and 1-year survival rate analysis, respectively. Results of meta-analysis showed that, arm GEMCOM's overall response rate and 1-year survival rate were higher than arm GEM's (z = 2.190, P = 0.028 vs. z = 4.400, P = 0.000). The differences were significant. The biases of the results were tested by Egger-test. The tests showed that no bias exists in both of two meta-analysis (t = 0.070, P = 0.946 and t = -0.740, P = 0.483) respectively.
CONCLUSIONThere is a possibility that the gemcitabine-combination is more effective than the gemcitabine on overall response rate and 1-year survival rate.
